Dr. Taniguchi is an Associate Professor at UT MD Anderson Cancer Center, with a joint appointment in Gastrointestinal Radiation Oncology and Experimental Radiation Oncology. He is a physician scientist specializing in gastrointestinal malignancies, with a clinical and research focus on pancreatic cancer. The Taniguchi Lab studies the biology of hypoxia (low oxygen) alters the response of normal tissues and the tumor microenvironment to chemotherapy and radiation. The lab. Has largely focused on the biology mediated by hypoxia-inducible factor-2 (HIF2), which reduces intestinal radiation injury and alters immune signaling in pancreatic tumors. The Taniguchi Lab collaborates closely with the lab of Dr. Emil Schueler to study the effects of radioprotectors along with FLASH RT. Dr. Taniguchi is the lead PI of three clinical trials focused on reducing normal tissue injury in radiation therapy.

Working as a medical physicist and post-doctoral fellow at the Heidelberg ion Beam Therapy Center (HIT), after 3 years spent at the Normandy Proton Therapy Center (Caen, France) as a lead medical physicist. Main works focus on the introduction of Helium ion therapy at HIT with support on clinical side (Commissioning/1st treatment in 2021) and research (RBE investigations to support clinical trial design). Research works related to FLASH radiotherapy with ions (protons, helium ions and carbon ions) with specific interest for the temporal dose-rate distribution of scanned ion beams (measurements and in-silico predictions) and its potential effect on the FLASH sparring effect (modelling, TPS implementation).

Graduated from Paris XI Orsay University. PhD thesis on leptoquarks and squarks searches in H1 at HERA(DESY). Work on particle physics experiments (CP asymmetry in BaBar at SLAC then calorimeter trigger for CMS at LHC(CERN)) Involved in developments for particle therapies since 2014, in particular transparent monitors for charged particle beams.

Michele Togno obtained his MSc at the university Politecnico di Milano, Italy, followed by a PhD in Physics at the Technische Universitaet Muenchen, Germany. He worked as R&D physicist for IBA Dosimetry GmbH until 2018, when he moved to Switzerland to join the Center for Proton Therapy (CPT) of Paul Scherrer Institut. In his current position, he is responsible and coordinator of the dosimetry activities at CPT, and participates in the development, clinical integration, commissioning and maintenance of the dosimetry equipment of the center. He is active member of the work party WP2 (Dose assessment, quality assurance, dummy runs, technology inventory) of the European Particle Therapy Network – a task force of ESTRO. Recently, his research work focused on the investigation of dosimeters response in ultra-high dose rate (FLASH) proton therapy beams.

Dr. Dejan Trbojevic - Senior Physicist 2013-to present at Brookhaven National Laboratory (BNL) - Tenured Physicist - 2003 - APS fellow 2008 - Principal Investigator for the CBETA (Cornell University Brookhaven National Laboratory Energy Recovery Linac Test Accelerator) Project. - PI of the LDRD Non-Scaling FFAG for eRHIC (2012-2014) - PI of the iRCMS - Ion Rapid Cycling Medical Synchrotron (2009-2015) - Deputy of the R&D eRHIC design team (2008-2016) - Head Commissioner of the Relativistic Heavy Ion Collider (RHIC) (1999-2000), at BNL - Key member of team designing and constructing RHIC (1992-1999) - Head of the Main Ring at Fermi National Laboratory (1988-1992) - General Manager of the D0 Overpass project (designed, built, and commissioned) - Ph. D. Physics, at Georgetown University, Washington D.C., Graduated 1984 - Georgetown University reconstructed and improved two Van der Graaf Accelerators, with energies of 400 KeV and 1 MeV. (1980 – 1984) - M.S Technical Physics - Electrotechnical University Belgrade Serbia, 1978 - B.S Electrotechnical University in Belgrade, Serbia 1972 - Transferred to BNL 1992, and member of the team to build and commissioned RHIC - Relativistic Heavy Ion Collider. - Owner of the six patents in the ion cancer therapy

Dr. Tubin is a 44-years-old board-certified radiation oncologist and scientific investigator from Austria, currently working as a director of clinical radiobiology and co-scientific director at the MedAustron Center for Particle Therapy and Research. His research interests include the use of photon-based stereotactic radiotherapy techniques and particles (protons, and especially carbon-ions) for induction of the immune-mediated non-targeted effects of radiotherapy: bystander and abscopal effects. Currently, he is a principle investigator of ongoing national and international, multi-centric, prospective studies on intentional induction of the abscopal and bystander effects among patients with oligometastatic and unrescetable bulky tumors. He graduated at the University of Rome (ITA) “La Sapienza” in 2008, and then finished the residency training also in Rome in 2012. During 2010-2011, he joined the University of Miami (USA) performing the preclinical in vitro and in vivo research on radiation-induced bystander and abscopal effects. The finding of those studies led to the development of a novel and unique technique for partial tumor irradiation targeting the hypoxic segment of bulky unresectable tumors for the clinical exploitation of bystander and abscopal effects. He was few times awarded for the best abstract presenting the preclinical and clinical findings related to this novel approach (2014 in Forli, ITA; 2016 in Klagenfurt, AUT; 2018 in Dublin, IRL; 2018 in Rimini, ITA; 2019 in Vienna, AUT). Dr. Tubin is currently leading the ESTRO focus group for innovative and unconventional radiotherapy techniques.